Effects of Hyperbilirubinemia on Visuocortical Functioning in High-Risk Infants
Effects of Hyperbilirubinemia on Visuocortical Functioning in High-Risk Infants
批准号:
10227981
负责人:
WILLIAM V GOOD
金额:
$65.12万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-09-01 至 2023-08-31
关键词:
AffectAgeAge-MonthsBilirubinBindingBirthBlood - brain barrier anatomyBlood CirculationBrainCarbon MonoxideChildCohort StudiesContrast SensitivityCytolysisDataDetectionDiseaseEnsureErythrocytesEventExclusion CriteriaFunctional disorderGestational AgeGoalsHemolysisHospitalsHourHumanHyperbilirubinemiaIcterusInfantKernicterusLaboratoriesLearningMeasurementMeasuresMediatingMonitorNeonatal JaundiceNervous system structureNeurologicNeurologic DysfunctionsNeurotoxinsPerceptionPhototherapyPlasmaPregnancyPremature InfantProductionResearchResolutionRetinaRetinal ConeRh DiseaseRiskSerum AlbuminSyndromeSystemTestingTimeToxic effectTransfusionVisionVisual evoked cortical potentialVisual system structurecohortexpectationexperiencefallshigh riskhigh risk infantinclusion criterianeonateneurotoxicitynovel strategiespersonalized approachpostnatal periodpublic health relevanceresponse
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Effects of hyperbilirubunemia on visuocortical functioning in high-risk infants
Abstract
Bilirubin in its unconjugated version can cross the blood-brain barrier (BBB), where it is a potent neurotoxin in
neonates. Levels of this substance are therefore closely monitored to ensure the neonate is not subject to
bilirubin encephalopathy, a potentially devastating event. Recently, effects on an infant's neurological system
that fall short of full-blown bilirubin encephalopathy have been described (syndromes of bilirubin-induced
neurologic dysfunction [BIND]). In a study from our laboratory, we showed that relatively low levels of total
serum/plasma bilirubin (TB) will produce undesired effects on visuocortical functioning. Since bilirubin is
usually cleared in infants within week of age, our findings of deleterious effects at 6 months and repeated at 12
months are potentially alarming. The cohort for this study was low-risk infants; i.e., those who were full-term,
healthy, and had no known hemolytic disease. Most of the children in this cohort did not qualify for therapy for
their elevated TB (phototherapy or exchange transfusion). In a subsequent preliminary study of jaundiced
preterm infants, we found that the effect on visuocortical functioning is much more pronounced than that seen
in full term infants. Two types of neonates are at particularly high-risk for BIND, and could show more
significant effects from bilirubin exposure: preterm infants, who have a more immature BBB (32–38 wks
gestational age at birth); and infants who have hemolytic disease will release larger quantities of bilirubin into
circulation. We will use the sweep visual evoked potential (sVEP) to measure 3 types of vision in these infants
at 6 months of age. Vernier acuity refers to the ability to see fine offsets of lines. Since the offsets are smaller
than the resolution afforded by the spacing of cone cells in the retina, the perception of these offsets requires
considerable cortical input. Contrast sensitivity and grating acuity are also important aspects of vision. All 3 are
subserved by different cortical mechanisms. We will measure acuity thresholds, conduction time,
suprathreshold changes, and other components of vision processing and compare these to bilirubin values
measured in the hospital and in the Stanford laboratory. This is a potentially highly significant study and could
affect the manner in which bilirubin is treated in certain neonates. The majority of premature infants have some
degree of hyperbilirubinemia, so the stakes are especially high. Since we don't know the level at which bilirubin
should be treated in a given infant, tests at Stanford, to include bilirubin binding capacity, TB, and unbound
bilirubin could pave the way to a more individualized approach to hyperbilirubinemia management. End-tidal
carbon monoxide levels will be measured for all infants in the study at the hospital and compared to sVEP
findings. This novel approach could pave the way to a noninvasive measure of bilirubin neurotoxicity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Effects of Hyperbilirubinemia on Visuocortical Functioning in High-Risk Infants
-
批准号:10468725
-
项目类别:
-
资助金额:$60.84万
-
财政年份:2019
-
负责人:WILLIAM V GOOD
-
依托单位:
Effects of Hyperbilirubinemia on Visuocortical Functioning in High-Risk Infants
-
批准号:9803368
-
项目类别:
-
资助金额:$70.43万
-
财政年份:2019
-
负责人:WILLIAM V GOOD
-
依托单位:
Neonatal Jaundice and Vision Loss
-
批准号:7774426
-
项目类别:
-
资助金额:$20.17万
-
财政年份:2010
-
负责人:WILLIAM V GOOD
-
依托单位:
Neonatal Jaundice and Vision Loss
-
批准号:8066603
-
项目类别:
-
资助金额:$23.03万
-
财政年份:2010
-
负责人:WILLIAM V GOOD
-
依托单位:
The Effects of Prematurity on Visual Development
-
批准号:6968858
-
项目类别:
-
资助金额:$42.03万
-
财政年份:2005
-
负责人:WILLIAM V GOOD
-
依托单位:
The Effects of Prematurity on Visual Development
-
批准号:7483009
-
项目类别:
-
资助金额:$34.97万
-
财政年份:2005
-
负责人:WILLIAM V GOOD
-
依托单位:
The Effects of Prematurity on Visual Development
-
批准号:7122341
-
项目类别:
-
资助金额:$42.12万
-
财政年份:2005
-
负责人:WILLIAM V GOOD
-
依托单位:
The Effects of Prematurity on Visual Development
-
批准号:7273560
-
项目类别:
-
资助金额:$42.39万
-
财政年份:2005
-
负责人:WILLIAM V GOOD
-
依托单位:
EARLY TMT RETINOPATHY OF PREMATURITY HEADQUARTER GRANT
-
批准号:7277196
-
项目类别:
-
资助金额:$20.51万
-
财政年份:1999
-
负责人:WILLIAM V GOOD
-
依托单位:
EARLY TMT RETINOPATHY OF PREMATURITY HEADQUARTER GRANT
-
批准号:6179064
-
项目类别:
-
资助金额:$11.08万
-
财政年份:1999
-
负责人:WILLIAM V GOOD
-
依托单位:
EARLY TMT RETINOPATHY OF PREMATURITY HEADQUARTER GRANT
-
批准号:6943843
-
项目类别:
-
资助金额:$20.18万
-
财政年份:1999
-
负责人:WILLIAM V GOOD
-
依托单位:
EARLY TMT RETINOPATHY OF PREMATURITY HEADQUARTER GRANT
-
批准号:2823240
-
项目类别:
-
资助金额:$12.05万
-
财政年份:1999
-
负责人:WILLIAM V GOOD
-
依托单位:
EARLY TMT RETINOPATHY OF PREMATURITY HEADQUARTER GRANT
-
批准号:6384789
-
项目类别:
-
资助金额:$12.19万
-
财政年份:1999
-
负责人:WILLIAM V GOOD
-
依托单位:
EARLY TMT RETINOPATHY OF PREMATURITY HEADQUARTER GRANT
-
批准号:7122448
-
项目类别:
-
资助金额:$20.22万
-
财政年份:1999
-
负责人:WILLIAM V GOOD
-
依托单位:
EARLY TMT RETINOPATHY OF PREMATURITY HEADQUARTER GRANT
-
批准号:6658961
-
项目类别:
-
资助金额:$17.64万
-
财政年份:1999
-
负责人:WILLIAM V GOOD
-
依托单位:
EARLY TMT RETINOPATHY OF PREMATURITY HEADQUARTER GRANT
-
批准号:6524962
-
项目类别:
-
资助金额:$17.24万
-
财政年份:1999
-
负责人:WILLIAM V GOOD
-
依托单位:
EARLY TMT RETINOPATHY OF PREMATURITY HEADQUARTER GRANT
-
批准号:7491019
-
项目类别:
-
资助金额:$20.81万
-
财政年份:1999
-
负责人:WILLIAM V GOOD
-
依托单位:
EARLY TMT RETINOPATHY OF PREMATURITY HEADQUARTER GRANT
-
批准号:6941010
-
项目类别:
-
资助金额:$19.42万
-
财政年份:1999
-
负责人:WILLIAM V GOOD
-
依托单位:
PEDIATRIC LOW VISION
-
批准号:6384235
-
项目类别:
-
资助金额:$15.53万
-
财政年份:1998
-
负责人:WILLIAM V GOOD
-
依托单位:
PEDIATRIC LOW VISION
-
批准号:6178713
-
项目类别:
-
资助金额:$15.53万
-
财政年份:1998
-
负责人:WILLIAM V GOOD
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: